and Human Services (HHS)
EXPIRED
Department of Health and Human Services
Participating Organizations
National Institutes of
Health (NIH), (http://www.nih.gov)
Components of Participating Organizations
National Institute of Allergy
and Infectious Diseases (NIAID), (http://www.niaid.nih.gov)
Announcement Type
New
Request For Applications (RFA) Number: RFA-AI-06-030
Catalog of Federal Domestic Assistance
Number(s)
93.855
Key Dates
Release/Posted
Date: March 30, 2006
Letters of Intent Receipt Date(s): Not
Applicable
Application
Receipt Date(s): May
15, 2006
Peer Review Date(s): June 30, 2006
Council
Review Date(s): August 2006
Earliest
Anticipated Start Date(s): September 19, 2006
Additional
Information To Be Available Date (Url Activation Date): http://www3.niaid.nih.gov/research/topics/radnuc/default.htm
Expiration Date: May 16, 2006
Due Dates for E.O. 12372
Not Applicable
Additional Overview
Content
Executive Summary
This is a funding opportunity announcement (FOA) to accelerate the development of safe and effective products to remove radionuclides from the body (decorporation) following nuclear contamination from any source. Specifically, candidate products will demonstrate an increase in efficiency and rate of radionuclide elimination from the body after contamination due to ingestion, inhalation or transdermal absorption.
Table of Contents
Part I
Overview Information
Part II Full Text of Announcement
Section I. Funding Opportunity
Description
1. Research Objectives
Section II. Award Information
1. Mechanism(s) of Support
2. Funds Available
Section III. Eligibility
Information
1. Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2.Cost Sharing or Matching
3. Other - Special Eligibility Criteria
Section IV. Application and
Submission Information
1. Address to Request Application Information
2. Content and Form of Application Submission
3. Submission Dates and Times
A. Receipt and Review and
Anticipated Start Dates
1. Letter
of Intent
B. Sending an Application to the
NIH
C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements
Section V. Application Review
Information
1. Criteria
2. Review and Selection Process
A. Additional Review Criteria
B. Additional Review
Considerations
C. Sharing Research Data
D. Sharing Research Resources
3. Anticipated Announcement and Award Dates
Section VI. Award Administration
Information
1. Award Notices
2. Administrative and National Policy Requirements
3. Reporting
Section VII. Agency Contact(s)
1. Scientific/Research Contact(s)
2. Peer Review Contact(s)
3. Financial/ Grants Management Contact(s)
Section VIII. Other Information
- Required Federal Citations
Part II
- Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
The Department of Health and
Human Services (DHHS) has assigned the NIH the responsibility to identify,
characterize, and develop new medical countermeasures against radiological or
nuclear attacks. A robust research and development program in this area will
begin to yield new diagnostic tools, radioprotectors and mitigators and
therapeutic agents to facilitate an effective response against radiological
injury. On October 14, 2004, the NIH convened an expert panel to review
the NIH Strategic Plan and Research Agenda for Medical Countermeasures
against Radiological and Nuclear Threats (http://www3.niaid.nih.gov/research/topics/radnuc/default.htm).
This strategic plan and research agenda outline a flexible, collaborative, and
comprehensive NIH research and product development program focused on medical
therapies and diagnostics to counter radiation injury. On behalf of the
NIH, the NIAID is charged with implementing this research agenda.
The goal of this research program is to develop candidates that will rapidly and efficiently eliminate radionuclide contamination from the human body (decorporation). The research program will focus specifically on candidates aimed at the elimination of a range of radionuclides and physicochemical forms of radionuclides that are relevant to accidental or intentional radioactive contamination and exposure as a result of malicious, criminal, terrorist, or nuclear attacks. Projects funded under this initiative will target the accelerated development of candidates that are likely to significantly advance progress toward this goal. Applicants must propose the development of previously identified candidates shown to have promise as effective chelation or decorporation agents. It is anticipated that candidates that prove efficacious will be advanced towards Food and Drug Administration (FDA) licensure through follow-on support from industry or other government-funded programs. For the purpose of this initiative, candidates are defined as drugs, chemicals, biologics, or other compounds with relevant chemical or biological properties. The NIAID will place a high priority on projects that demonstrate advantages over current treatments (such as, increased rates of radionuclide elimination, broader ranges of radionuclide decorporation, ease of mass casualty use, and/or reduced toxicity) and have a feasible product development plan for FDA licensure. Studies in animal models will be required to demonstrate radionuclide decorporation. Clinical studies and clinical trials will not be supported under this initiative.
Areas of product development that are responsive may include, but are not limited to, the following:
See Section VIII, Other Information - Required Federal
Citations, for policies related to this announcement.
Section
II. Award Information
1. Mechanism(s) of Support
This
funding opportunity will use the NIH R01 award mechanism. As an applicant, you will be
solely responsible for planning, directing, and executing the proposed project.
This
funding opportunity uses the just-in-time budget concepts. It also uses the
non-modular budget format described in the PHS 398 application instructions
(see http://grants.nih.gov/grants/funding/phs398/phs398.html).
A detailed categorical budget for the "Initial Budget Period" and the
"Entire Proposed Period of Support" is to be submitted with the
application.
2. Funds Available
The NIAID
intends to commit up to $4.0 million dollars in FY 2006 to support research and development
projects under this initiative. Applicants may request up to $1 million
in total costs for a project period not to exceed eighteen (18) months.
Although the financial plans of the IC(s) provide support
for this program, awards pursuant to this funding opportunity are contingent
upon the availability of funds and the receipt of a sufficient number of
meritorious applications.
Facilities
and administrative costs requested by consortium participants are not included
in the direct cost limitation, see NOT-OD-05-004.
Section
III. Eligibility Information
1. Eligible Applicants
1.A. Eligible Institutions
You may submit an
application if your organization has any of the following characteristics:
1.B. Eligible Individuals
Any individual with the
skills, knowledge, and resources necessary to carry out the proposed research
is invited to work with their institution to develop an application for
support. Individuals from underrepresented racial and ethnic groups as well as
individuals with disabilities are always encouraged to apply for NIH programs.
2. Cost Sharing or Matching
Not
applicable. The most current Grants Policy Statement can be found at: http://grants.nih.gov/grants/policy/nihgps_2003/nihgps_Part2.htm#matching_or_cost_sharing.
3. Other-Special Eligibility Criteria
An applicant may submit only
one application under this announcement and there is only one receipt date.
Section
IV. Application and Submission Information
1. Address to Request Application Information
The PHS 398 application
instructions are available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. Applicants must use the currently approved version of
the PHS 398. For further assistance contact GrantsInfo, Telephone (301)
710-0267, Email: [email protected].
Telecommunications for
the hearing impaired: TTY 301-451-5936.
2. Content and Form of Application Submission
Applications must be
prepared using the most current PHS 398 research grant application instructions
and forms. Applications must have a D&B Data Universal Numbering System
(DUNS) number as the universal identifier when applying for Federal grants or
cooperative agreements. The D&B number can be obtained by calling (866)
705-5711 or through the web site at http://www.dnb.com/us/.
The D&B number should be entered on line 11 of the face page of the PHS 398
form.
The title and number of this funding opportunity must
be typed on line 2 of the face page of the application form and the YES box
must be checked.
3. Submission Dates and Times
Applications must be
received on or before the receipt date described below (Section
IV.3.A). Submission times N/A.
3.A.
Receipt, Review and Anticipated Start Dates
Letter of Intent Receipt
Date: Not applicable
Application
Receipt Date(s): May 15, 2006
Peer
Review Date(s): June 30, 2006
Council
Review Date(s): August 2006
Earliest
Anticipated Start Date(s): September 19, 2006
3.A.1. Letter of Intent
Not applicable.
3.B.
Sending an Application to the NIH
Applications must be
prepared using the research grant applications found in the PHS 398
instructions for preparing a research grant application.
Send the signed original
application, five (5) paper copies, and one (1) CD with a faithful PDF file
copy to:
Kate White,
Ph.D.
Division of
Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 3131,
MSC-7616
6700B Rockledge Drive
Bethesda, MD 20892-7616 (USPS Express or regular mail)
Bethesda, MD 20817 (for express/courier service)
For Express
Couriers: 20817-1824
Phone:
301-435-1615
Fax:
301-402-2638
Email:
[email protected]
Personal deliveries of applications are no longer permitted (see http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-040.html).
NOTE: Applications must be sent to the above address and not to the Division of Receipt and Referral, Center for Scientific Review.
3.C. Application
Processing
Applications must be received on or before the
application receipt date(s) described above (Section IV.3.A.).
If an application is received after that date, it will be returned to the
applicant without review. Upon receipt, applications will be evaluated for
completeness and responsiveness by the NIAID. Incomplete and non-responsive applications will not be
reviewed.
4. Intergovernmental Review
This initiative is not
subject to intergovernmental
review.
5. Funding Restrictions
All NIH awards are
subject to the terms and conditions, cost principles, and other considerations
described in the NIH Grants Policy Statement. The Grants Policy Statement can
be found at http://grants.nih.gov/grants/policy/policy.htm.
Pre-Award Costs are
allowable. A grantee may, at its own risk and without NIH prior approval, incur
obligations and expenditures to cover costs up to 90 days before the beginning
date of the initial budget period of a new or competing continuation award if
such costs: are necessary to conduct the project, and would be allowable under
the grant, if awarded, without NIH prior approval. If specific expenditures
would otherwise require prior approval, the grantee must obtain NIH approval
before incurring the cost. NIH prior approval is required for any costs to be
incurred more than 90 days before the beginning date of the initial budget
period of a new or competing continuation award.
The incurrence of pre-award costs in anticipation of a
competing or non-competing award imposes no obligation on NIH either to make
the award or to increase the amount of the approved budget if an award is made
for less than the amount anticipated and is inadequate to cover the pre-award
costs incurred. NIH expects the grantee to be fully aware that pre-award costs
result in borrowing against future support and that such borrowing must not
impair the grantee's ability to accomplish the project objectives in the
approved time frame or in any way adversely affect the conduct of the project.
See NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part6.htm.
6. Other Submission Requirements
A letter application of no more than ten (10) pages must be submitted by May 15, 2006. The application must include the following sections, in the order listed, with an overall 10-page limit.
*PHS 398 FACE PAGE Must be completed and signed by the appropriate institutional officials (does not count against the page limit). The Face Page form requires a Dun and Bradstreet (D&B) Data Universal Numbering System (DUNS) number. Organizations that do not have a DUNS number may receive one at no cost by calling the dedicated toll-free DUNS number request line at 1-866-705-5711 or via URL http://www.dunandbradstreet.com. Additional information on this requirement is provided at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-055.html.
*PHS 398 PAGE 2 DESCRIPTION, KEY PERSONNEL, PERFORMANCE SITES, etc. (does not count against page limit).
*PHS 398 PAGES 4 AND 5 BUDGET PAGES (does not count against page limit).
Rationale Briefly outline the proposed project and describe its relevance to radionuclide decorporation due to accidental or intentional radiological contamination or nuclear terrorist attack, and its feasibility of obtaining FDA licensure for the radiation emergency indication.
Preliminary Data Describe existing experimental data that support the proposed experimental plan including any evidence that demonstrates the range of radionuclides chelated and/or decorporated, efficacy of decorporation, ease of administration, and safety of the proposed candidate medical countermeasure.
Research Plan Applications should include experimental plans sufficient to demonstrate the utility, efficacy or operational advantages of the proposed candidate medical countermeasure. Describe the experimental approaches to be undertaken, including a discussion of probable outcomes, potential pitfalls and limitations, approaches to overcome potential pitfalls and limitations, and alternative approaches.
Product Development Plan Briefly describe the proposed development plan for the eventual product and discuss the context of the proposed project within the overall development scheme.
Biographical Sketches Provide biographical sketches, not to exceed one (1) page each, for each individual proposed on the project. Provide evidence that the Principal Investigator is qualified to direct this product development effort (does not count against page limit).
Letters of Support For applications that include the use of a specific candidate for basic or regulated studies, applicants must also include letters of support from any collaborators and consultants participating in the proposed research, and corporate sponsors or individuals providing the candidate for the project (does not count against page limit).
*The PHS 398 Face Page form and the PHS 398 Page 2, and the PHS 398 Pages 4 and 5 Budget Pages, along with instructions for completing these forms, can be found at http://www3.niaid.nih.gov/biodefense/bioshield_forms.html.
Appendix materials are not allowed. Applications that contain appendix materials will be returned to the applicant without review. Applications must be complete. No materials will be accepted after the application receipt deadline.
The letter application must be single-spaced and single-sided, using type no smaller than 11 pt. font and margins no smaller than 0.5 inches on each side, top and bottom.
Additional Instructions and Information
Intellectual Property
NIAID recognizes that intellectual property rights are likely to play an important role in achieving the goals of this program. To this end, the NIAID reminds the applicant that:
To the extent that the project will involve partners, applicants are encouraged to reach early consensus with their proposed partners regarding intellectual property and other legal matters that may arise during the project. In addition, applicants are expected to exercise their Bayh-Dole rights in a manner that does not conflict with the goals of this award or the intent of the Bayh-Dole Act to promote the utilization, commercialization and availability of U.S. Government-funded inventions for public benefit. Finally, applicants are expected to make new information and materials known to the research community in a timely manner through publications, web announcements, and reports to the NIAID or other mechanisms.
Plan for Sharing
Research Data
Not Applicable
Sharing Research Resources
Not Applicable
Section V. Application Review Information
1. Criteria
Only the review criteria
described below will be considered in the review process.
The following will be
considered in making funding decisions:
2. Review and Selection Process
Applications that are
complete and responsive to the FOA will be evaluated for scientific and
technical merit by an appropriate peer review group convened by NIAID in accordance with the review
criteria stated below.
As part of the initial
merit review, all applications will:
The
goals of NIH supported research are to advance our understanding of biological
systems, to improve the control of disease, and to enhance health. In their written
critiques, reviewers will be asked to comment on each of the following criteria
in order to judge the likelihood that the proposed research will have a
substantial impact on the pursuit of these goals. Each of these criteria will
be addressed and considered in assigning the overall score, weighting them as
appropriate for each application. Note that an application does not need to be
strong in all categories to be judged likely to have major scientific impact
and thus deserve a high priority score. For example, an investigator may
propose to carry out important work that by its nature is not innovative but is
essential to move a field forward.
Significance: Does this study address an
important problem? If the aims of the application are achieved, how will
scientific knowledge or clinical practice be advanced? What will be the effect
of these studies on the concepts, methods, technologies, treatments, services,
or preventative interventions that drive this field?
Approach: Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well reasoned, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics
Innovation: Is the project original and innovative? For example: Does the project challenge existing paradigms or clinical practice; address an innovative hypothesis or critical barrier to progress in the field? Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?
Investigators: Are the investigators appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers? Does the investigative team bring complementary and integrated expertise to the project (if applicable)?
Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support?
2.A. Additional Review
Criteria:
In addition to the above
criteria, the following items will continue to be considered in the
determination of scientific merit and the priority score:
Applications will be reviewed on the basis of: the scientific rationale and technical feasibility of the proposed project to develop novel radionuclide decorporation agents, as well as the probability of technical success; the experience, expertise, and qualification of the project team; and the scientific environment and research facilities. Appropriateness in terms of the overall proposed project and stage of development, as well as the potential for further product development beyond that proposed in order to produce an FDA licensable radiation medical countermeasure, will also be assessed.
Care and
Use of Vertebrate Animals in Research: If vertebrate animals are to
be used in the project, the five items described under Section F of the PHS
Form 398 research grant application instructions will be assessed.
Biohazards: If materials or procedures
are proposed that are potentially hazardous to research personnel and/or the
environment, determine if the proposed protection is adequate.
2.B. Additional Review
Considerations
Budget: The reasonableness of the
proposed budget and the requested period of support in relation to the proposed
research. The priority score should not be affected by the evaluation of the
budget.
2.C. Sharing Research Data
Not Applicable
2.D. Sharing Research
Resources
Not Applicable
3. Anticipated Announcement and Award Dates
Not Applicable
Section
VI. Award Administration Information
1. Award Notices
After the peer review of
the application is completed, a successful PI will be able to access his or her
Summary Statement (written critique) via the eRA Commons.
Awards will be made on the basis of scientific merit as determined by peer review, availability of funds, as well as programmatic priorities.
If
the application is under consideration for funding, NIH will request
"just-in-time" information from the applicant. For details,
applicants may refer to the NIH Grants Policy Statement Part II: Terms and
Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part4.htm).
A formal notification in the form of a Notice
of Award (NoA) will be provided to the applicant organization. The NoA
signed by the grants management officer is the authorizing document. Once all
administrative and programmatic issues have been resolved, the NoA will be
generated via email notification from the awarding component to the grantee
business official (designated in item 12 on the Application Face Page). If a
grantee is not email enabled, a hard copy of the NoA will be mailed to the
business official.
Selection of an application for award is not an
authorization to begin performance. Any costs incurred before receipt of the
NoA are at the recipient's risk. These costs may be reimbursed only to the
extent considered allowable pre-award costs. See Also Section
IV.5. Funding Restrictions.
2. Administrative and National
Policy Requirements
All NIH grant and
cooperative agreement awards include the NIH Grants Policy Statement as part of
the NoA. For these terms of award, see the NIH Grants Policy Statement Part II:
Terms and Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part4.htm)
and Part II Terms and Conditions of NIH Grant Awards, Subpart B: Terms and
Conditions for Specific Types of Grants, Grantees, and Activities (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part9.htm).
3. Reporting
Not Applicable
Section
VII. Agency Contacts
We
encourage your inquiries concerning this funding opportunity and welcome the
opportunity to answer questions from potential applicants. Inquiries may fall
into three areas: scientific/research, peer review, and financial or grants
management issues:
1. Scientific/Research Contacts:
Bert W.
Maidment, Ph.D.
Division
of Allergy, Immunology, and Transplantation
National Institute of Allergy and Infectious Diseases
6610
Rockledge Drive,
Room 4055, MSC 6601
Bethesda, MD 20892-6601
Tel:
301-594-0641
Fax:
301-480-6597
Email: [email protected]
2. Peer Review Contacts:
Kate White, Ph.D.
Division of
Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 3131,
MSC-7616
6700B Rockledge Drive
Bethesda, MD 20892-7616 (USPS Express or regular mail)
Bethesda, MD 20817 (for express/courier service)
For Express
Couriers: 20817-1824
Phone:
301-435-1615
Fax:
301-402-2638
Email:
[email protected]
3. Financial or Grants Management Contacts:
Dawn Mitchum, MPH
Division
of Extramural Activities
National Institute of Allergy and Infectious Diseases
6700-B
Rockledge Drive,
Room 2241
Bethesda, MD 20892-7610
Tel:
301-451-2667
Fax:
301-493-0597
Email: [email protected]
Section VIII. Other Information
Required Federal Citations
Use of Animals in
Research:
Recipients of PHS
support for activities involving live, vertebrate animals must comply with PHS
Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf)
as mandated by the Health Research Extension Act of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm),
and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm)
as applicable.
Access to Research
Data through the Freedom of Information Act:
The Office of Management
and Budget (OMB) Circular A-110 has been revised to provide access to research
data through the Freedom of Information Act (FOIA) under some circumstances.
Data that are (1) first produced in a project that is supported in whole or in
part with Federal funds and (2) cited publicly and officially by a Federal
agency in support of an action that has the force and effect of law (i.e., a
regulation) may be accessed through FOIA. It is important for applicants to
understand the basic scope of this amendment. NIH has provided guidance at http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this funding opportunity in a
public archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the application.
In addition, applicants should think about how to structure informed consent
statements and other human subjects procedures given the potential for wider
use of data collected under this award.
NIH Public Access Policy:
NIH-funded investigators
are requested to submit to the NIH manuscript submission (NIHMS) system (http://www.nihms.nih.gov) at PubMed Central
(PMC) an electronic version of the author's final manuscript upon acceptance
for publication, resulting from research supported in whole or in part with
direct costs from NIH. The author's final manuscript is defined as the final
version accepted for journal publication, and includes all modifications from
the publishing peer review process.
NIH is requesting that
authors submit manuscripts resulting from 1) currently funded NIH research
projects or 2) previously supported NIH research projects if they are accepted
for publication on or after May 2, 2005. The NIH Public Access Policy applies
to all research grant and career development award mechanisms, cooperative
agreements, contracts, Institutional and Individual Ruth L. Kirschstein
National Research Service Awards, as well as NIH intramural research studies.
The Policy applies to peer-reviewed, original research publications that have
been supported in whole or in part with direct costs from NIH, but it does not
apply to book chapters, editorials, reviews, or conference proceedings.
Publications resulting from non-NIH-supported research projects should not be
submitted.
For more information
about the Policy or the submission process please visit the NIH Public Access Policy Web site at http://publicaccess.nih.gov/ and
view the Policy or other Resources and Tools including the Authors' Manual (http://publicaccess.nih.gov/publicaccess_Manual.htm).
URLs in NIH Grant
Applications or Appendices:
All applications and
proposals for NIH funding must be self-contained within specified page
limitations. Unless otherwise specified in an NIH solicitation, Internet
addresses (URLs) should not be used to provide information necessary to the
review because reviewers are under no obligation to view the Internet sites.
Furthermore, we caution reviewers that their anonymity may be compromised when
they directly access an Internet site.
Healthy People 2010:
The Public Health
Service (PHS) is committed to achieving the health promotion and disease
prevention objectives of "Healthy People 2010," a PHS-led national
activity for setting priority areas. This PA is related to one or more of the
priority areas. Potential applicants may obtain a copy of "Healthy People
2010" at http://www.health.gov/healthypeople.
Authority and
Regulations:
This program is described in
the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review. Awards are made under the
authorization of Sections 301 and 405 of the Public Health Service Act as
amended (42 USC 241 and 284) and under Federal Regulations 42 CFR 52 and 45 CFR
Parts 74 and 92. All awards are subject to the terms and conditions, cost
principles, and other considerations described in the NIH Grants Policy
Statement. The
NIH Grants Policy Statement can be found at http://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly
encourages all grant recipients to provide a smoke-free workplace and discourage
the use of all tobacco products. In addition, Public Law 103-227, the
Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some
cases, any portion of a facility) in which regular or routine education,
library, day care, health care, or early childhood development services are
provided to children. This is consistent with the PHS mission to protect and
advance the physical and mental health of the American people.
Loan Repayment
Programs:
NIH encourages
applications for educational loan repayment from qualified health professionals
who have made a commitment to pursue a research career involving clinical,
pediatric, contraception, infertility, and health disparities related areas.
The LRP is an important component of NIH's efforts to recruit and retain the
next generation of researchers by providing the means for developing a research
career unfettered by the burden of student loan debt. Note that an NIH grant is
not required for eligibility and concurrent career award and LRP applications
are encouraged. The periods of career award and LRP award may overlap providing
the LRP recipient with the required commitment of time and effort, as LRP
awardees must commit at least 50% of their time (at least 20 hours per week
based on a 40 hour week) for two years to the research. For further
information, please see: http://www.lrp.nih.gov.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||